Conference call scheduled for today at 8:30 a.m. ET - Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue - Adds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding…
Continue reading...